vs
拜玛林制药（BMRN）与RANGE RESOURCES CORP（RRC）财务数据对比。点击上方公司名可切换其他公司
拜玛林制药的季度营收约是RANGE RESOURCES CORP的1.1倍（$874.6M vs $786.9M），RANGE RESOURCES CORP净利率更高（22.8% vs -5.3%，领先28.1%），RANGE RESOURCES CORP同比增速更快（18.0% vs 17.0%），过去两年拜玛林制药的营收复合增速更高（16.1% vs 14.6%）
拜玛林制药是总部位于美国加利福尼亚州圣拉斐尔的生物技术企业，在美洲、亚洲、欧洲多地设有办事机构及生产设施，核心业务聚焦酶替代疗法研发，是全球首个推出Ⅰ型粘多糖贮积症治疗药物拉罗尼酶及苯丙酮尿症治疗药物的企业。
Range Resources Corporation是一家总部位于美国得克萨斯州沃斯堡的天然气勘探开采企业，核心运营区域为马塞勒斯页岩地层，是该地区拥有土地面积最大的运营商，专注于天然气资源的勘探、开发与生产业务，在北美油气开发领域具备深厚的行业积累。
BMRN vs RRC — 直观对比
营收规模更大
BMRN
是对方的1.1倍
$786.9M
营收增速更快
RRC
高出0.9%
17.0%
净利率更高
RRC
高出28.1%
-5.3%
两年增速更快
BMRN
近两年复合增速
14.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $874.6M | $786.9M |
| 净利润 | $-46.6M | $179.1M |
| 毛利率 | 68.5% | 94.5% |
| 营业利润率 | -5.1% | — |
| 净利率 | -5.3% | 22.8% |
| 营收同比 | 17.0% | 18.0% |
| 净利润同比 | -137.3% | 88.8% |
| 每股收益（稀释后） | $-0.22 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRNRRC
| Q4 25 | $874.6M | $786.9M | ||
| Q3 25 | $776.1M | $655.3M | ||
| Q2 25 | $825.4M | $699.6M | ||
| Q1 25 | $745.1M | $846.3M | ||
| Q4 24 | $747.3M | $667.0M | ||
| Q3 24 | $745.7M | $567.9M | ||
| Q2 24 | $712.0M | $513.2M | ||
| Q1 24 | $648.8M | $598.8M |
净利润BMRNRRC
| Q4 25 | $-46.6M | $179.1M | ||
| Q3 25 | $-30.7M | $144.3M | ||
| Q2 25 | $240.5M | $237.6M | ||
| Q1 25 | $185.7M | $97.1M | ||
| Q4 24 | $124.9M | $94.8M | ||
| Q3 24 | $106.1M | $50.7M | ||
| Q2 24 | $107.2M | $28.7M | ||
| Q1 24 | $88.7M | $92.1M |
毛利率BMRNRRC
| Q4 25 | 68.5% | 94.5% | ||
| Q3 25 | 82.0% | 92.5% | ||
| Q2 25 | 81.8% | 95.0% | ||
| Q1 25 | 79.7% | 93.1% | ||
| Q4 24 | 81.8% | 93.7% | ||
| Q3 24 | 74.7% | 94.3% | ||
| Q2 24 | 81.7% | 93.4% | ||
| Q1 24 | 80.7% | 94.7% |
营业利润率BMRNRRC
| Q4 25 | -5.1% | — | ||
| Q3 25 | -6.0% | — | ||
| Q2 25 | 33.5% | — | ||
| Q1 25 | 30.0% | — | ||
| Q4 24 | 21.6% | — | ||
| Q3 24 | 15.3% | — | ||
| Q2 24 | 16.9% | — | ||
| Q1 24 | 13.6% | — |
净利率BMRNRRC
| Q4 25 | -5.3% | 22.8% | ||
| Q3 25 | -4.0% | 22.0% | ||
| Q2 25 | 29.1% | 34.0% | ||
| Q1 25 | 24.9% | 11.5% | ||
| Q4 24 | 16.7% | 14.2% | ||
| Q3 24 | 14.2% | 8.9% | ||
| Q2 24 | 15.1% | 5.6% | ||
| Q1 24 | 13.7% | 15.4% |
每股收益（稀释后）BMRNRRC
| Q4 25 | $-0.22 | $0.75 | ||
| Q3 25 | $-0.16 | $0.60 | ||
| Q2 25 | $1.23 | $0.99 | ||
| Q1 25 | $0.95 | $0.40 | ||
| Q4 24 | $0.65 | $0.38 | ||
| Q3 24 | $0.55 | $0.21 | ||
| Q2 24 | $0.55 | $0.12 | ||
| Q1 24 | $0.46 | $0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $204.0K |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $6.1B | $4.3B |
| 总资产 | $7.6B | $7.4B |
| 负债/权益比越低杠杆越低 | — | 0.28× |
8季度趋势，按日历期对齐
现金及短期投资BMRNRRC
| Q4 25 | $1.3B | $204.0K | ||
| Q3 25 | $1.3B | $175.0K | ||
| Q2 25 | $1.2B | $134.0K | ||
| Q1 25 | $1.0B | $344.6M | ||
| Q4 24 | $942.8M | $304.5M | ||
| Q3 24 | $675.4M | $277.4M | ||
| Q2 24 | $972.1M | $251.1M | ||
| Q1 24 | $747.0M | $343.1M |
总债务BMRNRRC
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.8B |
股东权益BMRNRRC
| Q4 25 | $6.1B | $4.3B | ||
| Q3 25 | $6.1B | $4.2B | ||
| Q2 25 | $6.0B | $4.1B | ||
| Q1 25 | $5.8B | $3.9B | ||
| Q4 24 | $5.7B | $3.9B | ||
| Q3 24 | $5.4B | $3.9B | ||
| Q2 24 | $5.3B | $3.9B | ||
| Q1 24 | $5.1B | $3.8B |
总资产BMRNRRC
| Q4 25 | $7.6B | $7.4B | ||
| Q3 25 | $7.6B | $7.2B | ||
| Q2 25 | $7.5B | $7.1B | ||
| Q1 25 | $7.1B | $7.4B | ||
| Q4 24 | $7.0B | $7.3B | ||
| Q3 24 | $6.9B | $7.2B | ||
| Q2 24 | $7.1B | $7.3B | ||
| Q1 24 | $6.9B | $7.4B |
负债/权益比BMRNRRC
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.44× | ||
| Q1 24 | — | 0.46× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $99.6M | $257.5M |
| 自由现金流经营现金流 - 资本支出 | $58.9M | — |
| 自由现金流率自由现金流/营收 | 6.7% | — |
| 资本支出强度资本支出/营收 | 4.7% | — |
| 现金转化率经营现金流/净利润 | — | 1.44× |
| 过去12个月自由现金流最近4个季度 | $725.0M | — |
8季度趋势，按日历期对齐
经营现金流BMRNRRC
| Q4 25 | $99.6M | $257.5M | ||
| Q3 25 | $368.7M | $247.5M | ||
| Q2 25 | $185.3M | $336.2M | ||
| Q1 25 | $174.4M | $330.1M | ||
| Q4 24 | $185.6M | $217.9M | ||
| Q3 24 | $221.5M | $245.9M | ||
| Q2 24 | $118.8M | $148.8M | ||
| Q1 24 | $47.0M | $331.9M |
自由现金流BMRNRRC
| Q4 25 | $58.9M | — | ||
| Q3 25 | $340.2M | — | ||
| Q2 25 | $168.2M | — | ||
| Q1 25 | $157.6M | — | ||
| Q4 24 | $166.1M | — | ||
| Q3 24 | $203.0M | — | ||
| Q2 24 | $97.4M | — | ||
| Q1 24 | $20.9M | — |
自由现金流率BMRNRRC
| Q4 25 | 6.7% | — | ||
| Q3 25 | 43.8% | — | ||
| Q2 25 | 20.4% | — | ||
| Q1 25 | 21.2% | — | ||
| Q4 24 | 22.2% | — | ||
| Q3 24 | 27.2% | — | ||
| Q2 24 | 13.7% | — | ||
| Q1 24 | 3.2% | — |
资本支出强度BMRNRRC
| Q4 25 | 4.7% | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 2.3% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 3.0% | — | ||
| Q1 24 | 4.0% | — |
现金转化率BMRNRRC
| Q4 25 | — | 1.44× | ||
| Q3 25 | — | 1.72× | ||
| Q2 25 | 0.77× | 1.42× | ||
| Q1 25 | 0.94× | 3.40× | ||
| Q4 24 | 1.49× | 2.30× | ||
| Q3 24 | 2.09× | 4.85× | ||
| Q2 24 | 1.11× | 5.18× | ||
| Q1 24 | 0.53× | 3.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
RRC
| Natural Gas Natural Gas Liquids And Oil Sales | $745.5M | 95% |
| Brokered Natural Gas And Marketing | $41.3M | 5% |
